ABOUT EVENT
Here's what you missed at the 14th Clinical Biomarkers & CDx Europe
Europe’s Definitive Forum Spanning the End-to-End Development Hurdles for Biomarker Discovery & Companion Diagnostics
Despite the ever-changing regulatory landscape for companion diagnostics and IVD in Europe, the emergence of new technologies including AI, next generation sequencing and genetic-based diagnostics, coupled with a plethora of ground-breaking collaborations, places the field at an inflection point in which personalised medicines for all patients is on the horizon.
Leverage world-leading insight from senior executives across 2-days and 2 tracks. Attendees got to choose between unravelling deeper mechanistic understanding and novel tools for biomarker ID, or strategic level considerations for CDx market access and reimbursement, on a per talk basis.
FULL AGENDA
What's Was New for 2024?
A case study into how pharma is responding to IVDR regulations to continue clinical trials in Europe, delving into lessons learned and best practices with Executive Director IVD and Director of CDx Portfolio Management co-presenters at Regeneron
Director of Precision Medicine Access Strategy at Johnson & Johnson exploring how to maximize evidence generation to support novel biomarker & diagnostics access strategy
Novel techniques for biomarker profiling to promote translational success genome wide cfDNA methylome profiling as a tool in precision oncology with the Deputy Director, CR-UK National Biomarker Centre
Exploration into the key impacts IVDR is having on shortages of CE marked IVDs and in-house assays, and approval timelines with the Director of Precision Medicine at AstraZenca
Network with the entire CB & CDx Community:
